ATE401913T1 - Behandlung oder prävention von unplanmässigen blutungen bei frauen unter progestogenhaltiger medikation - Google Patents

Behandlung oder prävention von unplanmässigen blutungen bei frauen unter progestogenhaltiger medikation

Info

Publication number
ATE401913T1
ATE401913T1 AT04774969T AT04774969T ATE401913T1 AT E401913 T1 ATE401913 T1 AT E401913T1 AT 04774969 T AT04774969 T AT 04774969T AT 04774969 T AT04774969 T AT 04774969T AT E401913 T1 ATE401913 T1 AT E401913T1
Authority
AT
Austria
Prior art keywords
progestogen
women
unscheduled bleeding
dosage unit
ras
Prior art date
Application number
AT04774969T
Other languages
English (en)
Inventor
Morris Notelovitz
Bennink Herman Coelingh
Petrus Boerrigter
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of ATE401913T1 publication Critical patent/ATE401913T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/553—Renin inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04774969T 2004-09-27 2004-09-27 Behandlung oder prävention von unplanmässigen blutungen bei frauen unter progestogenhaltiger medikation ATE401913T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2004/000667 WO2006036054A1 (en) 2004-09-27 2004-09-27 Treatment of prevention of unscheduled bleeding in women on progestogen containing medication

Publications (1)

Publication Number Publication Date
ATE401913T1 true ATE401913T1 (de) 2008-08-15

Family

ID=34958752

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04774969T ATE401913T1 (de) 2004-09-27 2004-09-27 Behandlung oder prävention von unplanmässigen blutungen bei frauen unter progestogenhaltiger medikation

Country Status (8)

Country Link
US (1) US20090197843A1 (de)
EP (1) EP1796725B1 (de)
AT (1) ATE401913T1 (de)
CA (1) CA2581927C (de)
DE (1) DE602004015343D1 (de)
ES (1) ES2310293T3 (de)
PL (1) PL1796725T3 (de)
WO (1) WO2006036054A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170830A1 (en) * 2006-04-03 2011-05-30 Novartis Ag Renin inhibitors for the treatment of hypertension
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy

Also Published As

Publication number Publication date
CA2581927A1 (en) 2006-04-06
EP1796725A1 (de) 2007-06-20
WO2006036054A1 (en) 2006-04-06
ES2310293T3 (es) 2009-01-01
CA2581927C (en) 2013-04-09
EP1796725B1 (de) 2008-07-23
US20090197843A1 (en) 2009-08-06
PL1796725T3 (pl) 2009-01-30
DE602004015343D1 (de) 2008-09-04

Similar Documents

Publication Publication Date Title
ATE401913T1 (de) Behandlung oder prävention von unplanmässigen blutungen bei frauen unter progestogenhaltiger medikation
Grbic et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program
DE69942009D1 (de) Verbindungen für die behandlung von gewichtsverlust
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
TNSN00010A1 (fr) DIPHENYLUREE A SUBSTITUTION ω CARBOXYARYLE SERVANT D'INHIBUTEURS DE RAF KINASE.
CY1117925T1 (el) Μεθοδος αγωγης και βιοπροσδιορισμος που σχετιζεται με παραγοντα αναστολης της μεταναστευσης των μακροφαγων (mif) ως προερχομενο απο την καρδια μυοκαρδιακο κατασταλτικο παραγοντα
EP3530288A3 (de) Verfahren zur behandlung von leiden in zusammenhang mit masp-2-abhängiger komplementaktivierung
ATE314062T1 (de) Zusammensetzungen zur abgabe von cortisolantagonisten
WO2001062234A8 (en) Dosing regimen
MXPA06001815A (es) Preparado farmaceutico transdermico que contiene combinaciones de principios activos para el tratamiento de la enfermedad de parkinson.
ATE506065T1 (de) Verfahren zur behandlung oder vorbeugung von symptomen hormoneller veränderungen
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
WO2020186132A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
DE60035996D1 (de) Diätetisches kalzium als ergänzung zu vitamin d verbindungen bei der behandlung von multipler sklerose
WO2004009773A3 (en) Methods and compositions for activating or inhibiting vegf-d and vegf-c
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
SG160323A1 (en) Methods for controlling angiogenesis and cell proliferation
DE60029937D1 (de) Angiotensin ii und analoga zur begrenzung von narben und adhäsionbildung
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation
WO2001044270A3 (en) Methods for treating and preventing diabetic complications by use of angiotensin-related peptides

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties